Ferronova
Developing magnetic nanoparticle tracers and a handheld magnetometer system for image-guided cancer surgery.
Website: https://www.ferronova.com.au/
Cover Block
Public sources
| Field | Value |
|---|---|
| Name | Ferronova |
| Tagline | Developing magnetic nanoparticle tracers and a handheld magnetometer system for image-guided cancer surgery. |
| Headquarters | Adelaide, Australia |
| Founded | 2016 |
| Stage | Series A |
| Business Model | Hardware + Software |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | Oceania |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding Label | Series A |
| Total Disclosed | A$11.4 million [Crunchbase] |
Links
Public sources
- Website: https://www.ferronova.com.au/
- LinkedIn: https://au.linkedin.com/company/ferronova
Executive Summary
PUBLIC Ferronova is developing a magnetic tracer and handheld detection system for cancer surgery, and it merits investor attention because it is moving from academic proof into later-stage clinical validation with a long-running Series A and multiple grant-backed development programs already in place [University of South Australia] [Startup Daily, December 2025] [BioSpectrum Asia, January 2023]. The company was founded in 2016 as a spin-out from the University of South Australia and Victoria University of Wellington, which matters here because the product architecture appears to come directly from the originating research collaboration rather than from a thin commercialization layer added later [University of South Australia] [Wellington UniVentures, July 2018].
Its core platform combines magnetic nanoparticle tracers with an ultrasensitive handheld magnetometer probe to help surgeons identify sentinel lymph nodes and metastatic spread during surgery, a positioning that is differentiated in the cited materials by its radiation-free workflow and by claims that the tracer can remain in lymph nodes for extended periods [Wellington UniVentures, July 2018] [PRNewswire, July 2026] [LSI Asia Summit Presenting Companies]. Public materials indicate initial focus across stomach and oesophageal surgery, with additional work cited in head-and-neck, brain, colorectal, breast, and oral cancer settings, although the most concrete near-term evidence sits in upper gastrointestinal trials rather than broad commercial deployment [BioSpectrum Asia, January 2023] [National Imaging Facility] [Startup Daily, December 2025].
The founding bench is tied closely to the underlying science: Bernard "Benjamin" Thierry is identified as a founder, Richard Tilley as a founding figure, and Aidan Cousins as co-founder and senior research engineer with responsibility for technical development of the companion probe system, which suggests a team with deep product familiarity even if public evidence on commercial leadership remains limited [Ferronova] [Startup Intros] [LinkedIn, retrieved 2026]. On capitalization, Ferronova has raised institutional and grant funding across seed and Series A financings, with Startup Daily reporting total Series A funding of A$17.5 million by December 2025; investors named across the record include Uniseed, Renew Pharmaceuticals, Artesian Venture Partners, UniSuper, and the South Australian Venture Capital Fund [Startup Daily, December 2025] [Uniseed, May 2020] [BioSpectrum Asia, January 2023].
The business model reads as hardware plus software within surgical oncology, but the nearer commercial question is clinical adoption and regulatory progress rather than software monetization. Over the next 12 to 18 months, the key public markers to watch are completion and readout of the MAGMAP trial, evidence that upper gastrointestinal data translate into broader indication expansion, and any shift from grant-and-equity financing toward named clinical or hospital adoption milestones [Startup Daily, December 2025] [Yahoo Finance, July 2026] [PRNewswire, July 2026].
Lightly corroborated -- Section draws on multiple public sources for company history, funding, and trial status, but some product and team details rely on company materials or single-source ecosystem coverage.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series A |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | Oceania |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding | Total disclosed approximately A$11.4 million |
How the Company Got Here
PUBLIC
Ferronova enters the file as a university spinout first and a financing story second. The company was founded in 2016 in Adelaide, Australia, commercialising research from the University of South Australia and Victoria University of Wellington around magnetic cancer-detection technology for surgery [University of South Australia] [Crunchbase]. Its public company materials describe a system built around magnetic nanoparticle tracers and a handheld magnetometer intended to help surgeons identify cancer cells and lymph nodes during procedures [Ferronova] [Crunchbase].
The early chronology is reasonably clear even if the cap table is not. Ferronova announced its spinout in June 2016 with backing linked to Powerhouse Ventures and collaborators in New Zealand, then received A$500,000 from the South Australian Early Stage Commercialisation Fund in July 2018, according to Wellington UniVentures [Ferronova, June 2016] [Wellington UniVentures, July 2018]. Crunchbase also lists the company as headquartered in Adelaide and founded in 2016, which aligns with the institutional origin story [Crunchbase].
The next visible milestones are clinical and financing oriented. Uniseed said in May 2020 that it had led a A$3.5 million Series A round for Ferronova, and the company later disclosed additional Series A financings that brought total Series A funding to A$17.5 million by December 2025, according to Startup Daily [Uniseed, May 2020] [Ferronova] [Crunchbase]. Public materials also indicate the company has been advancing FerroTrace through clinical studies in upper gastrointestinal cancers while broadening its oncology ambitions [Ferronova] [Crunchbase].
Lightly corroborated -- Confirmed in part by Crunchbase and Ferronova company materials, with additional chronology support from University of South Australia, Wellington UniVentures, and Uniseed.
Product and Technology
MIXED
Ferronova is building a surgical oncology system around two linked components: a magnetic nanoparticle tracer and a handheld magnetometer intended for use during cancer surgery [Wellington UniVentures, July 2018] [University of South Australia] [PRNewswire, July 2026]. In plain terms, the tracer is administered so clinicians can identify lymph nodes draining a primary tumour, and the probe is then used to detect those magnetically labelled nodes in tissue during the procedure [PRNewswire, July 2026] [Wellington UniVentures, July 2018]. Public descriptions consistently position the product for image-guided surgery rather than broad diagnostics, with the near-term clinical focus in stomach and oesophageal cancers and additional stated interest in head-and-neck and brain applications [BioSpectrum Asia, January 2023] [BioSpectrum Asia, October 2026].
The technical differentiation, insofar as the public record supports it, sits less in software and more in the tracer-plus-detector pairing. Wellington UniVentures describes the platform as combining iron-core magnetic nanoparticles with an ultrasensitive magnetometer probe [Wellington UniVentures, July 2018], while later company and third-party materials describe FerroTrace as a lymphatic tracer designed to support sentinel node mapping and intraoperative decision-making [LSI Asia Summit Presenting Companies] [Victor Windeyer - Perennial Partners | LinkedIn, retrieved 2026] [PRNewswire, July 2026]. Some of the stronger product-performance language, including retention in lymph nodes for more than six months and the absence of toxicity-related adverse events in a 62-patient gastric and oesophageal trial, appears in lower-corroboration or company-adjacent sources and should be treated as promising but still provisional until peer-reviewed clinical data are available [LSI Asia Summit Presenting Companies] [Macau Business].
The evidence base is strongest around intended use and ongoing clinical validation. Startup Daily reported that Ferronova had enrolled 54 of 60 patients in a two-year stomach and oesophageal cancer trial by December 2025, with completion expected in early 2026 [Startup Daily, December 2025], and Yahoo Finance later reported trial enrolment had been completed [Yahoo Finance, July 2026]. That leaves the core product story relatively clear for investors: Ferronova is not selling a general-purpose imaging platform today, it is trying to prove that a magnetic tracer workflow can improve surgical staging and node detection in defined cancer procedures, with commercial value likely to depend on clinical evidence and operating-room adoption rather than on software alone [BioSpectrum Asia, October 2026] [PRNewswire, July 2026].
Lightly corroborated -- Core product architecture and clinical use are corroborated by Wellington UniVentures, Startup Daily, PRNewswire, and University of South Australia, but several performance-oriented claims rely on company or single-source materials.
Where the Demand Sits
PUBLIC
This market matters now because Ferronova sits at the intersection of two durable spending priorities in oncology, better intraoperative decision support and less toxic localization methods, while its public progress still rests more on clinical validation than on a disclosed market map [BioSpectrum Asia, January 2023] [Startup Daily, December 2025]. Ferronova is developing magnetic nanoparticle tracers and a handheld magnetometer system for image-guided cancer surgery, with early public focus on gastric and oesophageal cancers and broader stated interest in head-and-neck and brain cancers [Wellington UniVentures, July 2018] [BioSpectrum Asia, January 2023]. That places it inside surgical oncology and lymph-node mapping workflows rather than a general diagnostics market, which matters because adoption will likely be governed by procedure economics, evidence thresholds, and operating-room workflow fit, not only by tracer performance claims [PRNewswire, July 2026] [Uniseed, May 2020].
The usual TAM, SAM, and SOM framing is thin here because the supplied sources do not include a named third-party market-sizing report for magnetic surgical tracers or magnetometer-guided lymphatic mapping. The cleaner read is to anchor on analogous public markets rather than force precision the evidence does not support. Ferronova's system is described as helping clinicians identify sentinel lymph nodes and metastatic spread during surgery, which makes the closest adjacent markets sentinel lymph node mapping, image-guided surgery, and intraoperative oncology tools [PRNewswire, July 2026] [BioSpectrum Asia, January 2023]. Publicly, the company's opportunity looks less like a broad hospital software rollout and more like a procedure-linked medtech market that expands indication by indication as clinical data matures [Startup Daily, December 2025] [Yahoo Finance, July 2026].
Demand drivers are visible in the problem statement the clinical program is trying to solve. Ferronova's public materials and investor coverage describe a tracer intended to help surgeons locate cancer cells and lymph nodes that may be difficult to detect, with one cited product characteristic being retention in lymph nodes for more than six months, aimed at settings where neoadjuvant treatment can reduce the utility of other tracers [BioSpectrum Asia, January 2023] [LSI Asia Summit Presenting Companies] [Macau Business]. If that claim continues to hold in broader datasets, the commercial appeal would come from fitting cancers where accurate nodal staging and cleaner resections have outsized downstream consequences for recurrence risk and treatment planning [BioSpectrum Asia, January 2023] [PRNewswire, July 2026]. The public evidence also suggests a practical tailwind in radiation-free localization, which may position magnetic tracing as an alternative in workflows that currently depend on nuclear medicine logistics [Ferronova] [PRNewswire, July 2026].
The adjacent and substitute markets are easier to define than the core market size. Ferronova can be read as competing indirectly with standard-of-care radioactive tracers, blue dyes, and other intraoperative localization methods used in sentinel node mapping and surgical staging, even though the supplied sources do not name specific competitors [Macau Business] [PRNewswire, July 2026]. The company has also signaled work across oral, colorectal, breast, upper gastrointestinal, and brain-related applications, which broadens the adjacent opportunity set but also raises the evidence burden because each cancer pathway has distinct surgeon habits, reimbursement logic, and regulatory expectations [National Imaging Facility] [Ferronova] [BioSpectrum Asia, January 2023]. In practice, that means the obtainable market is likely to open sequentially through indications and geographies rather than all at once.
Regulatory and macro signals are favorable, but still pre-commercial. Ferronova has attracted repeated non-dilutive support, including A$500,000 from the South Australian Early Stage Commercialisation Fund in 2018, A$826,000 from the Australian Government's BioMedTech Horizons program in 2020, and a A$3 million CRC-P grant in 2023 [Wellington UniVentures, July 2018] [University of South Australia] [BioSpectrum Asia, January 2023]. That pattern does not prove demand, but it does indicate policy interest in domestic medtech translation and gives the company more runway to push evidence generation before full commercial scale [University of South Australia] [Technews180]. The near-term market gating factor remains clinical proof and regulatory progression: by December 2025, a 60-patient, two-year upper gastrointestinal trial had enrolled 54 patients, with completion expected in early 2026, and later reporting said enrolment was completed in 2026 [Startup Daily, December 2025] [Yahoo Finance, July 2026].
| Public market signal | Figure | Relevance |
|---|---|---|
| South Australian Early Stage Commercialisation Fund grant | A$500,000 | Early translational support for commercialization pathway [Wellington UniVentures, July 2018] |
| BioMedTech Horizons grant | A$826,000 | Federal support for further nanoparticle development and first-in-human work [University of South Australia] |
| CRC-P grant | A$3,000,000 | Government-backed support for clinical and commercialization progress [BioSpectrum Asia, January 2023] |
| Upper GI clinical trial target | 60 patients | Indicates initial indication-specific market entry path rather than broad launch [Startup Daily, December 2025] |
| Enrolled by Dec. 2025 | 54 patients | Shows progress, but also that market readiness still depended on trial completion at that point [Startup Daily, December 2025] |
The table is less a sizing model than a signal map. Public evidence points to a market being built through grant-backed clinical validation and narrow procedural entry points, which is typical for surgical oncology platforms and a reminder that the commercial question is timing, not only technical fit.
Lightly corroborated -- Section relies on named public sources including Wellington UniVentures, BioSpectrum Asia, Startup Daily, PRNewswire, Yahoo Finance, Uniseed, and University of South Australia, but no independent third-party TAM report was provided and several product-market framing points rest on company or event materials.
Competitive Landscape
MIXED Ferronova sits in a narrower lane than broad surgical imaging platforms, competing less on general operating-room workflow and more on whether a magnetic tracer-plus-probe stack can become a preferred method for finding sentinel or metastatic lymph nodes in hard-to-stage cancers [Wellington UniVentures, July 2018] [PRNewswire, July 2026].
The public record does not name direct startup competitors, which limits any clean like-for-like market map. What is visible is the category structure around Ferronova's wedge. At one end are incumbent standards in cancer surgery, including conventional lymph node mapping and pathology-led staging workflows, which Ferronova is trying to improve by giving surgeons an intraoperative signal on lymphatic spread [BioSpectrum Asia, October 2026] [PRNewswire, July 2026]. At the other end are adjacent substitutes such as radiotracer-based approaches, which remain embedded in parts of surgical oncology, and broader image-guided oncology tools that address tumor localization without necessarily using magnetic tracers [LSI Asia Summit Presenting Companies] [Ferronova].
Within that structure, Ferronova's public differentiation is technical rather than commercial. The company says FerroTrace is designed to remain in lymph nodes for more than six months, a property presented as useful when neoadjuvant treatment makes other tracers less effective, and multiple public sources describe the platform as radiation-free and centered on magnetic nanoparticle tracing with a handheld magnetometer companion device [LSI Asia Summit Presenting Companies] [Ferronova] [Wellington UniVentures, July 2018]. If those claims continue to hold in clinical settings, the edge is potentially meaningful in upper gastrointestinal cancers and other indications where pre-surgical treatment complicates node identification. The durability of that edge is less settled. It rests on clinical evidence, regulatory progress, and surgeon adoption, not on a visible distribution moat or disclosed installed base [Startup Daily, December 2025] [Yahoo Finance, July 2026].
The company's strongest defensible asset today appears to be its translational positioning around a specific clinical problem rather than scale. Ferronova was spun out of the University of South Australia and Victoria University of Wellington in 2016, and the technology originated from collaboration between researchers working on the magnetometer and nanoparticle tracer components [University of South Australia] [Wellington UniVentures, July 2018]. That academic origin matters because magnetic detection in surgery is a system-level problem, not a single-component one. A tracer without a reliable probe, or a probe without a clinically useful tracer, is less compelling. Still, this remains a perishable edge unless the company converts technical integration into trial readouts, regulatory clearances, and reference sites that later entrants would struggle to match [Startup Daily, December 2025] [PRNewswire, July 2026].
The main exposure is straightforward. Ferronova does not yet appear, from the public record, to own the hospital channel, to disclose commercial deployments, or to name health-system customers, which leaves room for larger medtech incumbents or better-distributed oncology tool vendors to move faster once the category is validated [LinkedIn] [Startup Daily, December 2025]. The company is also concentrated in proving one thesis: that magnetic node mapping materially improves surgical decision-making in difficult cancers. If future buyers decide existing radiotracer or imaging workflows are adequate, or if adoption is confined to a narrow set of surgeons and centers, Ferronova's category could remain clinically interesting but commercially bounded [BioSpectrum Asia, October 2026] [PRNewswire, July 2026].
The most plausible 18-month competitive scenario is that the field remains evidence-led, with hospitals and investors rewarding whichever platform best translates trial data into workflow adoption. On the public evidence, Ferronova is the likely winner if MAGMAP and related studies continue to show safe use and clinically useful node detection in cancers where current mapping methods are constrained, because its differentiation is most explicit in that setting [Macau Business] [PRNewswire, July 2026]. The likely loser if trial momentum stalls is not a named rival but the standalone magnetic-tracer category itself, since the available sources do not yet identify another visible company carrying the same public narrative into this exact niche. That is an unusual competitive setup. It gives Ferronova more room to define the category, but also leaves the company carrying the burden of proof largely on its own [Startup Daily, December 2025] [BioSpectrum Asia, October 2026].
Opportunity
PUBLIC The prize here is not a better surgical accessory, but a chance to become part of the clinical workflow for cancer surgery if Ferronova can prove that magnetic tracing changes staging and treatment decisions across multiple tumor types [University of South Australia] [Startup Daily, December 2025] [PRNewswire, July 2026].
The headline opportunity is a platform position in image-guided oncology, starting with sentinel lymph node mapping and extending into broader intraoperative decision support. Ferronova was spun out of the University of South Australia and Victoria University of Wellington in 2016, and its core system pairs magnetic nanoparticle tracers with a handheld magnetometer rather than relying on a single disposable product line [University of South Australia] [Wellington UniVentures, July 2018]. That makes the upside more credible than a one-indication device story: the same underlying approach has been described across stomach, oesophageal, head-and-neck, brain, oral, colorectal, and breast cancer settings, while the company has continued to attract follow-on financing and non-dilutive support as it advances clinical evidence [BioSpectrum Asia, January 2023] [National Imaging Facility] [Startup Daily, December 2025].
The evidence still points to a company in validation mode, not commercial scale. But the reach of the ambition is visible in the trial progression: Startup Daily reported 54 of 60 patients enrolled in Ferronova's two-year stomach and oesophageal cancer study as of December 2025, with completion expected in early 2026, and later reporting said patient enrolment was completed [Startup Daily, December 2025] [Yahoo Finance, July 2026]. Preliminary findings from the MAGMAP multi-centre trial were announced in July 2026, which suggests the company is moving from technical promise toward a dataset that hospitals, surgeons, and eventual commercial partners can evaluate in practice [PRNewswire, July 2026].
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Win upper GI surgery first | Ferronova becomes a standard adjunct in gastric and oesophageal cancer surgery at specialist centers, with FerroTrace and the companion probe used to identify sentinel nodes and guide staging | Publication and dissemination of MAGMAP results after enrolment completion and preliminary findings [PRNewswire, July 2026] [Yahoo Finance, July 2026] | The company already ran a dedicated 60-patient upper GI trial, reported 54 enrolled by December 2025, and later announced preliminary trial findings, indicating a real clinical wedge rather than a purely preclinical thesis [Startup Daily, December 2025] [PRNewswire, July 2026] |
| Expand indication by indication | Ferronova uses one validated magnetic-tracer platform to move from upper GI into oral, colorectal, breast, and potentially brain applications, increasing instrument utilization across surgical departments | Additional investigator-led studies or first-in-human work funded by grants and existing backers [University of South Australia] [National Imaging Facility] | Sources tie the technology to multiple cancers, and the 2020 BioMedTech Horizons grant was described as supporting further nanoparticle development and first-in-human colorectal work, which supports a multi-indication path [University of South Australia] [Ferronova] |
| Become a strategic oncology tool partner | A larger medtech, imaging, or oncology tools company uses Ferronova's tracer-plus-detector stack as a clinical platform for image-guided surgery and adjacent radiotherapy workflows | More mature clinical data plus evidence of interoperability or adjacent applications, including Ferronova's Purdue-linked FAP inhibitor radiotherapy work [Ferronova] [PRNewswire, July 2026] | The company is already operating at the intersection of tracers, detection hardware, and oncology workflow, and its public materials show willingness to build around a broader image-guided cancer treatment stack rather than a single product SKU [Ferronova] [Wellington UniVentures, July 2018] |
The table points to a simple pattern. Ferronova does not need to win all of surgical oncology at once. One high-need indication with convincing data can establish procedural legitimacy, and that can support reuse of the same tracer logic, probe workflow, and hospital relationships in adjacent cancers [PRNewswire, July 2026] [National Imaging Facility].
What compounding looks like is clinical, not consumer. If Ferronova demonstrates that its nanoparticles remain in lymph nodes for extended periods and stay useful even after neoadjuvant treatment, as presented by LSI Asia Summit materials, that solves a specific problem for cancers where timing and treatment sequencing make conventional tracers less informative [LSI Asia Summit Presenting Companies]. In that case, each successful indication could improve the case for the next one: more surgeons trained on the workflow, more institutional comfort with the hardware, more publications, and a broader body of safety and efficacy evidence around FerroTrace and the companion probe [Macau Business] [PRNewswire, July 2026].
There is also a funding flywheel in the public record. Ferronova has repeatedly combined venture backing with grant support, including the South Australian Early Stage Commercialisation Fund, the BioMedTech Horizons program, and a A$3 million CRC-P grant reported in January 2023 [Wellington UniVentures, July 2018] [University of South Australia] [BioSpectrum Asia, January 2023]. That matters because a capital-intensive medtech company with both hardware and clinical programs benefits when each data milestone can unlock a mix of strategic, venture, and public funding rather than relying on one source alone.
The size of the win is best framed as a strategic platform outcome rather than a near-term revenue multiple. Ferronova's disclosed Series A funding had reached A$17.5 million by December 2025, according to Startup Daily, which is modest relative to the ambition implied by a multi-indication oncology platform [Startup Daily, December 2025]. If the company establishes a repeatable standard for magnetic node mapping and intraoperative detection across several solid-tumor workflows, the result could support a materially larger medtech outcome than its capital raised to date suggests, potentially at the level where strategic acquirers view it as a workflow asset rather than a single-product tuck-in (scenario, not a forecast) [Startup Daily, December 2025] [PRNewswire, July 2026]. Public sources here do not provide a clean named comparable or market-cap benchmark, so the more disciplined reading is that the upside depends on Ferronova crossing from promising clinical program to adopted surgical platform.
Lightly corroborated -- Section relies on corroborated public reporting from Startup Daily, PRNewswire, Wellington UniVentures, University of South Australia, and other named sources, but several product-expansion claims remain supported by single-source or company-linked materials.
Sources
Public sources
[Startup Daily, December 2025] Adelaide cancer detection startup Ferronova tops up its long-running Series A with 6 million | https://www.startupdaily.net/topic/funding/adelaide-cancer-detection-startup-ferronova-tops-up-its-long-running-series-a-with-6-million/
[BioSpectrum Asia, January 2023] Australian biotech startup Ferronova secures A$11 M to advance nanotech image-guided cancer therapy | https://www.biospectrumasia.com/news/98/21814/australian-biotech-startup-ferronova-secures-a11-m-to-advance-nanotech-image-guided-cancer-therapy.html
[Wellington UniVentures, July 2018] Tracing a path to success | https://www.wellingtonuniventures.nz/news/tracing-a-path-to-success/
[PRNewswire, July 2026] Ferronova announces preliminary findings from MAGMAP multi-centre trial | https://www.prnewswire.com/
[National Imaging Facility] Ferronova clinical trials profile | https://anif.org.au/project/ferronova/
[Uniseed, May 2020] Ferronova closes A$3.5m Series A to develop breakthrough cancer surgery technology | https://www.uniseed.com/ferronova-closes-a3-5m-series-a-to-develop-breakthrough-cancer-surgery-technology/
[Yahoo Finance, July 2026] Ferronova completes patient enrolment for two-year trial to progress commercialisation of FerroTrace | https://finance.yahoo.com/
[Crunchbase] Ferronova | Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/ferronova
[Ferronova, June 2016] Ferronova’s magnet cancer detection device draws investors | https://www.ferronova.com.au/news/ferronovas-magnet-cancer-detection-device-draws-investors/
[University of South Australia] Ferronova spin-out profile | https://www.unisa.edu.au/
[LinkedIn, retrieved 2026] Fredrik Nyberg | LinkedIn | https://www.linkedin.com/in/nyberg/
Articles about Ferronova
- A Radiation-Free Tracer Passes Its First 62-Patient Cancer Trial — The Australian spinout's nanoparticle system, designed to find elusive lymph nodes, has cleared a key safety milestone in gastric and oesophageal cancers.